+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
U

Actively Recruiting

This research aims to evaluate how well Virtual Reality VR can reduce pain and anxiety during painful procedures in patients with blood cancers, such as hematological malignancies. The study focuses on procedures like Bone Marrow Biopsy, Bone Marrow Aspiration, Lumbar Puncture, Venipuncture, and chemotherapy. Previous research suggests VR may help distract patients from pain and improve their overall experience during medical care. The trial uses a crossover design where each patient experiences two periods one with standard care and one with the addition of a VR session during the same procedure. There is also an external control group receiving only standard care, matched by age and procedure type for comparison. The VR intervention involves a headset connected to a smartphone that displays immersive visual and audio content tailored to the study population. Each VR session lasts as long as the painful procedure. Participants will undergo assessments of pain levels using a Numeric Rating Scale just before and after procedures. Anxiety will be measured with a standardized inventory before and after procedures as well. The study includes a washout period of at least seven days between the two treatment periods. Researchers will monitor how pain and anxiety change with and without VR distraction. The overall participation time varies depending on the procedures and scheduling.

Age: 6Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating ABO-101 for safety, tolerability, how the body processes it, and its effects in people with primary hyperoxaluria type 1 PH1, a rare genetic condition. The study is a Phase 12 trial sponsored by Arbor Biotechnologies and consists of two main study periods to carefully assess the medication in adults and children. In the first study period, adults receive a single ascending dose to determine the best dose in Part A. Then, in Part B, children receive the recommended dose identified from adults. After these initial treatments, participants enter a long-term monitoring phase to meet local and national requirements and observe ongoing effects. Participants will undergo intravenous infusions of ABO-101, followed by regular evaluations including safety checks for any side effects up to six months, and measurements of urinary oxalate and plasma glycolate levels. Kidney function and immune responses to the drug will also be monitored over 12 to 24 months. The total study duration includes initial dosing and extended follow-up to understand the treatments impact and safety over time.

Age: 6Years - 64YearsAll GendersPhase 1Phase 2
7 locations
V

Actively Recruiting

Heart failure is a common and serious condition that leads to many hospital visits and deaths worldwide. Access to specialized heart failure clinics is limited, although such care can improve patient outcomes. This international, multicenter randomized controlled trial called VICTORY-HF is studying whether adding a virtual heart failure clinic to routine care can improve medication use and health outcomes for patients recently discharged after hospitalization or urgent care for heart failure. Participants will be randomly assigned to receive either 90 days of virtual heart failure clinic care plus routine care or routine care alone. The virtual clinic offers structured remote follow-up, monitoring of physiological measures, and optimization of guideline-directed medical therapies. The trial will evaluate the effects of this intervention on medication use, patient-reported health status, mortality, hospital readmissions, and emergency visits. Participants will be followed for 90 days during the virtual clinic intervention, with co-primary outcomes measured at 90 and 180 days. Assessments include monitoring of clinical events, medication optimization, and healthcare utilization. The follow-up period includes clinic visits and data collection to evaluate the impact of virtual care on recovery and health status after heart failure hospitalization.

Age: 18Years +All GendersPhase Not Applicable
9 locations